Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 5;24(7):e00034-17.
doi: 10.1128/CVI.00034-17. Print 2017 Jul.

Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases

Affiliations

Waning Immunity and Microbial Vaccines-Workshop of the National Institute of Allergy and Infectious Diseases

Xin-Xing Gu et al. Clin Vaccine Immunol. .

Abstract

Since the middle of the 20th century, vaccines have made a significant public health impact by controlling infectious diseases globally. Although long-term protection has been achieved with some vaccines, immunity wanes over time with others, resulting in outbreaks or epidemics of infectious diseases. Long-term protection against infectious agents that have a complex life cycle and antigenic variation remains a key challenge. Novel strategies to characterize the short- and long-term immune responses to vaccines and to induce immune responses that mimic natural infection have recently emerged. New technologies and approaches in vaccinology, such as adjuvants, delivery systems, and antigen formulations, have the potential to elicit more durable protection and fewer adverse reactions; together with in vitro systems, these technologies have the capacity to model and accelerate vaccine development. The National Institute of Allergy and Infectious Diseases (NIAID) held a workshop on 19 September 2016 that focused on waning immunity to selected vaccines (for Bordetella pertussis, Salmonella enterica serovar Typhi, Neisseria meningitidis, influenza, mumps, and malaria), with an emphasis on identifying knowledge gaps, future research needs, and how this information can inform development of more effective vaccines for infectious diseases.

Keywords: Bordetella pertussis; Neisseria meningitidis; Salmonella; adjuvants; immunity; influenza; malaria; mumps; vaccines.

PubMed Disclaimer

References

    1. Landry S, Heilman C. 2005. Future directions in vaccines: the payoffs of basic research. Health Aff (Millwood) 24:758–769. doi:10.1377/hlthaff.24.3.758. - DOI - PubMed
    1. Roush SW, Murphy TV. 2007. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298:2155–2163. doi:10.1001/jama.298.18.2155. - DOI - PubMed
    1. Nabel GJ. 2013. Designing tomorrow's vaccines. N Engl J Med 368:551–560. doi:10.1056/NEJMra1204186. - DOI - PMC - PubMed
    1. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. 2015. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 33:246–251. doi:10.1016/j.vaccine.2014.06.052. - DOI - PMC - PubMed
    1. Schwartz KL, Kwong JC, Deeks SL, Campitelli MA, Jamieson FB, Marchand-Austin A, Stukel TA, Rosella L, Daneman N, Bolotin S, Drews SJ, Rilkoff H, Crowcroft NS. 2016. Effectiveness of pertussis vaccination and duration of immunity. CMAJ 188:E399–E406. doi:10.1503/cmaj.160193. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources